NDEI.org

Premier destination for HCP diabetes education that addresses knowledge and practice gaps to enhance patient care

  • Home
  • Expert Commentary > NDEI.org Expert Commentary on the JUPITER trial Peter Libby


  • Printer-Friendly Format
  • Email to a Colleague

EXPERT COMMENTARY

Peter Libby, MD, on statins and diabetes risk in JUPITER 

 

Dr Libby 

Peter Libby, MD 

The Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study tested the hypothesis that targeting statin therapy on the basis of inflammatory status could provide an effective way of identifying individuals without prior cardiovascular (CV) disease, otherwise considered at low risk of CV events, who could nonetheless benefit from therapy. The study showed overwhelming benefit for the individuals in the group treated with rosuvastatin 20 mg per day who were selected for participation in the study because they had no prior CV disease, an LDL-C level <130 mg/dL, but evidence of smoldering inflammation as gauged by a high sensitivity C-reactive protein (hsCRP) ≥2 mg/L.1 The primary publication of this study pointed out a statistically significant increase in investigator-identified new-onset diabetes. A1C during the trial was 5.8% in the placebo group and 5.9% in the rosuvastatin group, a modest difference, but one that was statistically significant as more than 17,000 individuals participated in this study, yielding considerable statistical power. 

After publication of JUPITER, a number of well-conducted meta-analyses established that all statins tested accelerate the development of diabetes.2,3 The risk of developing new-onset diabetes appeared approximately proportional to the degree of LDL-lowering efficacy of the statins.  

These results led to widespread concern among the medical community and the general public regarding the potential of statins to “cause” diabetes. In 2012, the US Food and Drug Administration issued a public statement affirming “a small increased risk of raised blood sugar levels and the development of type 2 diabetes” in association with the use of statins.4  

The JUPITER data set provided an opportunity to answer two critically important clinical questions regarding statins and diabetes: (1) are certain individuals at particular risk for developing diabetes, and (2) do individuals who develop diabetes show net health benefit from statin treatment? The recent Lancet publication from the JUPITER investigators provided answers to these key queries.5 Those who developed diabetes in JUPITER were “on the road” to this diagnosis, having one or more major risk factors for developing diabetes. Those with no risk factors for diabetes, and with A1C in the normal range at baseline, did not have an increased risk of developing diabetes. Indeed, the data showed that individuals randomized to rosuvastatin developed diabetes just 5.4 weeks earlier than their placebo-treated counterparts. The patients with major risk factors for diabetes enjoyed as much CV event and death reduction as those without such risk factors, indicating that the benefits of statin therapy exceed the diabetes hazard—including in individuals who had a high risk of developing diabetes.  

These data should put the diabetes risk from statin therapy in perspective. Lifestyle modification remains the cornerstone of risk reduction for both diabetes and atherosclerotic CV disease events. But in my weighing of the evidence, withholding statins from individuals at risk for or with diabetes, who meet current criteria, deprives them of a treatment with the potential of reducing heart attack, stroke, and death.  

References
1. Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.

2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.

3. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-2564.

4. FDA. FDA expands advice on statin risks. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm. Accessed September 5, 2012.

5. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.
 

Peter Libby, MD, is Chief, Cardiovascular Medicine at Brigham and Women’s Hospital and Mallinckrodt Professor of Medicine at Harvard Medical School in Boston, Massachusetts. 

Dr Libby is an unpaid consultant or involved in clinical trials for Amgen, AstraZeneca, Genzyme, GlaxoSmithKline, Merck, Novartis, Pfizer, ProNova and Sigma-Tau; he is a member of the scientific advisory boards for Athera Biotechnologies, Carolus Therapeutics, Interleukin Genetics, and BIND Biosciences. 

We value your feedback! Please click here to complete our brief survey and let us know your thoughts about this program.

The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual package inserts for use outside of the United States. 

September 2012  

This content was not associated with funding via an educational grant or a promotional/commercial interest. 

Related content on the JUPITER trial: 

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk? 

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein  

JUPITER: Design  

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?  

JUPITER Analysis: Design  

JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor  

JUPITER Analysis: Increased Diabetes Risk With ≥1 Risk Factor* at Baseline  

JUPITER Analysis: Incident Diabetes by Treatment Group  

JUPITER Analysis: Average Time to Diabetes Diagnosis  

JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor  

JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor  

JUPITER Analysis: CV Risk Reduction Among Subjects Who Developed Diabetes  

JUPITER Analysis: Conclusions  

 JUPITER Analysis: Limitations  

JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale  

JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile  

JUPITER: Study Design  

JUPITER Results: Primary Endpoint  

JUPITER Results: Components of Primary Endpoint  

JUPITER: Lipid and Hs-CRP Levels  

JUPITER Results: Summary  

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials 

Statin Use and Risk for Diabetes: Design 

Statin Use and Risk for Diabetes: Results 

Back to
Expert Commentary 

BG Footer

 

 



Partner Site
CCMDweb.org


Sign Up
Please enter both email/username and
password to log in


Forgot Password?
  • Slide Library
  • Expert Commentary
  • Clinical Guidelines
  • Conference Coverage
  • Case Studies
  • Patient Education
  • Glossary
  • Product Indications
  • Professional Resources
  • Press Room
  • Calendar of Events
  • CME Opportunities





  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

  • Home
  • About NDEI
  • Site Map
  • FAQ
  • Contact Us
  • Slide Library
  • Expert Commentary
  • Clinical Guidelines
  • Conference Coverage
  • Case Studies
  • Patient Education
  • Glossary
  • Product Indications
  • Professional Resources
  • Press Room
  • Calendar of Events
  • CME Opportunities

Sponsored by Ashfield Healthcare Communications, Lyndhurst, NJ. Copyright © 2016 Ashfield Healthcare Communications. All rights reserved.

  • Editorial Policy
  • Advertising Policy
  • Disclaimer Statement
  • Privacy Statement